FDA Cites Lupin Plant Following Inspection

Source: Economic Times

Mar 18, 2016

India's Lupin announced it has received nine observations relating to inadequacy and adherence to operating norms for its manufacturing plant in Goa from the U.S. FDA.

Lupin noted that the observations are on aspects such as inadequacy and adherence to standard operating procedures. FDA observations are made when in the investigator’s judgement, conditions or practices observed would indicate that any drug or device has been adulterated or is being prepared, packed, or held under conditions whereby it may become adulterated.

The Goa facility supplies over 100 products to several regulated markets, including the U.S. and EU.

Following the announcement, Lupin stock fell on speculation that key investor Rakesh Jhunjhunwala is selling some of his 7.42 million Lupin shares.

Read the ET article

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments